Tislelizumab plus chemotherapy for patients with EGFR -mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy.

Hua ZhongXueyan ZhangPanwen TianTianqing ChuQisen GuoXinmin YuZhuang YuYalun LiLijuan ChenJie LiuYan ZhangYan GuanXun ShiJing WangYanqiu ZhaoBao-Hui Han

Published in: Journal for immunotherapy of cancer (2023)

-mutated non-squamous NSCLC after EGFR TKI failure.

Keyphrases

small cell lung cancer
tyrosine kinase
epidermal growth factor receptor
advanced non small cell lung cancer
high grade
brain metastases
low grade
stem cells
squamous cell carcinoma
locally advanced
wild type
cell therapy